0001178913-24-002647.txt : 20240815 0001178913-24-002647.hdr.sgml : 20240815 20240815081514 ACCESSION NUMBER: 0001178913-24-002647 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240815 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240815 DATE AS OF CHANGE: 20240815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ReWalk Robotics Ltd. CENTRAL INDEX KEY: 0001607962 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36612 FILM NUMBER: 241210710 BUSINESS ADDRESS: STREET 1: 200 DONALD LYNCH BLVD. CITY: MARLBOROUGH STATE: X1 ZIP: MA 01752 BUSINESS PHONE: 15082511154 MAIL ADDRESS: STREET 1: 200 DONALD LYNCH BLVD. CITY: MARLBOROUGH STATE: X1 ZIP: MA 01752 FORMER COMPANY: FORMER CONFORMED NAME: Argo Medical Technologies Ltd. DATE OF NAME CHANGE: 20140513 8-K 1 zk2431866.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 15, 2024
 
ReWalk Robotics Ltd.
(Exact name of registrant as specified in its charter)
  
Israel
001-36612
Not applicable
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
 
 
200 Donald Lynch Blvd. Marlborough, MA
 
01752
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: +508.251.1154
  
Not applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:

Securities registered pursuant to
Section 12(b) of the Exchange Act
 
Trading symbol
 
Name of each exchange on which registered
Ordinary Shares, par value NIS 1.75
 
LFWD
 
Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
  
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

Item 2.02 Results of Operations and Financial Condition.
 
On August 15, 2024, ReWalk Robotics Ltd. (the “Company,” “we” or “us”) issued a press release announcing its financial results for the second quarter ended June 30, 2024. A copy of the press release is being furnished herewith as Exhibit 99.1. As set forth in the press release, the Company will host a conference call to discuss its financial results for the second quarter ended June 30, 2024, on August 15, 2024 at 8:30 a.m. E.D.T. The archived webcast will be available at  https://edge.media-server.com/mmc/p/i8mtrha9 and/or through the Company’s website at www.golifeward.com under the “Investors” section for 30 days after the completion of the call.
 
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “1934 Act”), nor shall it be deemed “incorporated by reference” into any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as may be expressly set forth by specific reference in such filing.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
 
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
   
*
Furnished herewith
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
ReWalk Robotics Ltd.
 
 
 
 
 
Dated: August 15, 2024
By:
/s/ Michael Lawless
 
 
Name:
Michael Lawless
 
 
Title:
Chief Financial Officer
 
 
 EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1
Exhibit 99.1


Lifeward Reports Second Quarter 2024 Financial Results

Record ReWalk revenue with 20 systems placed
 
Q2’24 revenue of $6.7M up over 400% compared to $1.3M in Q2’23
 
Medicare claims for submissions from prior quarters beginning to be paid

MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, August 15, 2024 – ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced its financial results for the three months and six months ended June 30, 2024.
 
Recent Highlights and Milestones for Lifeward
 

 •
The CMS Home Health Rule and Medicare Pricing achieved by Lifeward is now fully functional with widespread approvals and the beginning of payments from our 2023 and first-half 2024 submissions.
 

 •
With the experience of access for Medicare beneficiaries, physicians are now able to actively write prescriptions with confidence that on-label SCI individuals have access to this innovative walking and stair climbing technology.
 

 •
In June, Lifeward successfully launched the latest generation of Differential Air Pressure Anti-Gravity Technology with its new NEO product line. The NEO provides features that are aligned for independent clinics seeking to offer this advanced technology.
 

 •
In June, Lifeward completed its FDA submission for its 7th generation ReWalk design which will further enhance use of the system in all aspects of daily life and further establish Lifeward as the most experienced personal exoskeleton company in the world.
 
“We are succeeding with the basics of execution with building a Medicare processing pipeline and by successfully getting paid. In addition our integration of two companies has expanded our scale and positions us well for the coming quarters” said Larry Jasinski, Chief Executive Officer of Lifeward. “The ability to drive growth and to cut and leverage expenses are the meaningful output of these achievements.
 
Second Quarter 2024 Financial Results

Revenue was $6.7 million in the second quarter of 2024, compared to $1.3 million during the second quarter of 2023, up $5.4 million, or over 400%. Revenue from the sale of its historical products and services including ReWalk exoskeletons, MyoCycles, and ReStore exo-suits was $3.1 million, up $1.8 million, or 131% compared to the prior year. This performance was primarily driven by an increase in ReWalk system revenue from the expansion of access through Medicare coverage.  Revenue from the sale of AlterG products and services was $3.6 million, a sequential improvement of $0.8 million vs. the first quarter of 2024.  The Company expects continued sequential improvement in sales effectiveness through the rest of 2024 as further impact of the commercial integration activity takes hold.

 
Gross margin was 41.1% during the second quarter of 2024, compared to 43.1% in the second quarter of 2023. On a non-GAAP basis, which excludes the amortization of purchase price allocation adjustments and stock compensation expense listed in the attached non-GAAP reconciliation table, adjusted gross margin was 46.9% in the second quarter of 2024, compared to 43.3% in the second quarter of 2023, a 3.6 percentage point increase. This improvement is primarily attributable to higher volumes of ReWalk product sales which resulted in greater absorption of operations and overhead costs.
 
Total operating expenses in the second quarter of 2024 were $7.2 million, compared to $5.7 million in the second quarter of 2023.  On a non-GAAP basis, which excludes the items listed in the attached non-GAAP reconciliation table, adjusted operating expenses were $6.9 million in the second quarter of 2024, compared to $4.5 million in the second quarter of 2023, a $2.3 million increase.  This increase is primarily due to the addition of headcount and outside spending from the acquisition of AlterG and investment in additional commercial resources.
 
Operating loss in the second quarter of 2024 was $4.4 million, compared to $5.2 million in the second quarter of 2023. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted operating loss was $3.7 million in the second quarter of 2024, compared to a loss of $3.9 million in the second quarter of 2023.
 
Net loss was $4.3 million, or $0.50 per share, for the second quarter of 2024, compared to a net loss of $4.6 million, or $0.55 per share, in the second quarter of 2023. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted net loss was $3.6 million, or $0.42 per share, in the second quarter of 2024, compared to $3.4 million, or $0.40 per share, during the second quarter of 2023.
 
Liquidity
 
As of June 30, 2024, ReWalk had $15.1 million in unrestricted cash and cash equivalents on its balance sheet with no debt.  During the second quarter of 2024, cash used in operations was $5.6 million, which was adversely affected by long lead times required by the Medicare Administrative Contractors to set up and commence initial claims payments. At the end of the second quarter of 2024, Lifeward had $2.6 million of accounts receivable for Medicare claims that had been submitted in 2023 and the first half of 2024 which have begun to be paid subsequent to the end of the second quarter.
 
Financial Guidance
 
Following the results of the second quarter of 2024, Lifeward continues to expect full year revenue of between $28 million to $32 million in 2024.  Based on the expanded access to ReWalk systems from the recently established Medicare coverage and continued improvement of sales traction by the new commercial team, Lifeward expects sequential improvement in quarterly revenue through the rest of 2024.
 
Conference Call
 
Lifeward management will host its conference call as follows:
 
Date
August 14, 2024
Time
8:30 AM EDT
Telephone
U.S:
1-833-316-0561
 
International:
1-412-317-0690
 
Israel:
1-80-9212373
 
Germany:
0800-6647560
Access code
Please reference the “Lifeward Earnings Call”
Webcast (live, listen-only and archive)
https://edge.media-server.com/mmc/p/i8mtrha9

The archived webcast will be available via the following https://edge.media-server.com/mmc/p/i8mtrha9 or through the “Investors” section on our website at GoLifeward.com.


About Lifeward
 
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity systems, the ReStore Exo-Suit, and the MyoCycle FES Systems.
 
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.

ReWalk®, ReStore® and Alter G® are registered trademarks of ReWalk Robotics Ltd. (DBA Lifeward) and/or its affiliates.

Forward-Looking Statements
 
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: the Company’s ability to realize the anticipated benefits of the acquisition of AlterG, including the possibility that the expected benefits of the acquisition will not be realized within the expected time period or at all; the effect of the AlterG acquisition on the ability of the Company to retain customers and key personnel and to maintain relationships with suppliers, distributors and other key business relations; potential litigation in connection with the AlterG acquisition; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company’s ability to manage challenges and expenses associated with activist shareholder activities, including litigation; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2023 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

 
Non-GAAP Financial Measures
 
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), the Company believes that the use of non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers to as non-GAAP financial measures, are not prepared in accordance with GAAP.
 
Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, the Company believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense and acquisition costs allows for more meaningful comparisons between operating results from period to period. Each of the Company’s non-GAAP financial measures is an important tool for financial and operational decision-making and for the Company’s evaluation of its operating results over different periods of time. The non-GAAP financial data are not measures of the Company’s financial performance under U.S. GAAP and should not be considered as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in ReWalk’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on the Company’s reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company’s business and an important part of the compensation provided to its employees.
 
The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. ReWalk urges investors to review the reconciliation of the Company’s non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate the Company’s business.
 
Lifeward Media Relations:
LifeSci Communications
E: media@golifeward.com

Lifeward Investor Contact:
Mike Lawless
Chief Financial Officer
Lifeward
E: ir@golifeward.com



ReWalk Robotics Ltd. And subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)

   
Three Months Ended
    
Six Months Ended
  
   
June 30,
    
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
                         
Revenue
  
$
6,707
    
$
1,337
    
$
11,990
    
$
2,567
  
Cost of revenues
    
3,950
      
761
      
7,838
      
1,420
  
Gross profit
    
2,757
      
576
      
4,152
      
1,147
  
Operating expenses:
                                
Research and development, net
    
1,205
      
816
      
2,496
      
1,568
  
Sales and marketing
    
4,403
      
2,504
      
9,417
      
4,988
  
General and administrative
    
1,592
      
2,414
      
3,184
      
4,124
  
Total operating expenses
    
7,200
      
5,734
      
15,097
      
10,680
  
Operating loss
    
(4,443
)
    
(5,158
)
    
(10,945
)
    
(9,533
)
Financial income, net
    
144
      
558
      
376
      
636
  
Loss before income taxes
    
(4,299
)
    
(4,600
)
    
(10,569
)
    
(8,897
)
Taxes on income
   
5
      
42
      
11
      
66
  
Net loss
  
$
(4,304
)
  
$
(4,642
)
  
$
(10,580
)
  
$
(8,963
)
Net loss per ordinary share, basic and diluted
  
$
(0.50
)
  
$
(0.55
)
  
$
(1.23
)
  
$
(1.05
)
Weighted average number of shares used in computing
net loss per ordinary share basic and diluted (1)
    
8,608,937
      
8,502,201
      
8,599,520
      
8,502,184
  

(1) Reflects our one-for-seven reverse share split that became effective on March 15, 2024.

ReWalk Robotics Ltd. And subsidiaries
Condensed Consolidated Balance Sheets
(In thousands)

   
June 30,
   
December 31,
 
   
2024
    
2023
  
   
(Unudited)
    
(Audited)
  
Assets
            
Current assets
            
Cash and cash equivalents
  
$
15,131
    
$
28,083
  
Trade receivables, net
    
5,269
      
3,120
  
Prepaid expenses and other current assets
    
2,046
      
2,366
  
Inventories
    
7,193
      
5,653
  
Total current assets
    
29,639
      
39,222
  
Restricted cash and other long term assets
    
430
      
784
  
Operating lease right-of-use assets
    
1,257
      
1,861
  
Property and equipment, net
    
1,257
      
1,262
  
Intangible Assets
    
10,862
      
12,525
  
Goodwill
    
7,538
      
7,538
  
Total assets
  
$
50,983
    
$
63,192
  
Liabilities and equity
                
Current liabilities
                
Trade payables
    
4,849
      
5,069
  
Current maturities of operating leases
    
1,167
      
1,296
  
Other current liabilities
    
3,954
      
4,854
  
Earnout
    
-
      
576
  
Total current liabilities
    
9,970
      
11,795
  
                 
Non-current operating leases
    
123
      
607
  
Earnout
    
2,800
      
2,716
  
Other long-term liabilities
    
1,403
      
1,564
  
Shareholders’ equity
    
36,687
      
46,510
  
Total liabilities and equity
  
$
50,983
    
$
63,192
  


ReWalk Robotics Ltd. And subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)

   
Six Months Ended
  
   
June 30,
  
   
2024
    
2023
  
             
Net cash used in operating activities
  
$
(13,290
)
  
$
(8,739
)
                 
Net cash used in financing activities
    
-
      
(986
)
                 
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash
    
(15
)
    
5
  
Decrease in cash, cash equivalents, and restricted cash
    
(13,305
)
    
(9,720
)
Cash, cash equivalents, and restricted cash at beginning of period
    
28,792
      
68,555
  
Cash, cash equivalents, and restricted cash at end of period
  
$
15,487
    
$
58,835
  

ReWalk Robotics Ltd. And subsidiaries
(Unaudited)
(In thousand)

   
Three Months Ended
    
Six Months Ended
  
   
June 30,
    
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
                         
Revenues based on customer’s location:
                        
United States
    
3,849
      
924
      
7,596
      
1,801
  
Europe
    
2,308
      
411
      
3,477
      
735
  
Asia - Pacific
    
214
      
1
      
394
      
29
  
Rest of the world
    
336
      
1
      
523
      
2
  
Total Revenues
  
$
6,707
    
$
1,337
    
$
11,990
    
$
2,567
  

   
Three Months Ended
    
Six Months Ended
  
   
June 30,
    
June 30,
  
Dollars in thousands, except per share data
  
2024
    
2023
    
2024
    
2023
  
                         
GAAP net loss
  
$
(4,304
)
  
$
(4,642
)
  
$
(10,580
)
  
$
(8,963
)
Adjustments:
                                
Amortization of intangible assets
    
832
      
-
      
1,663
      
-
  
M&A transaction
    
-
      
894
      
(467
)
    
1,044
  
Integration/Rebranding costs
    
-
      
-
      
236
      
-
  
Remeasurement of earnout liability
    
(488
)
    
-
      
(492
)
    
-
  
Stock-based compensation expenses
    
376
      
318
      
757
      
622
  
                                 
Non-GAAP net loss
  
$
(3,584
)
  
$
(3,430
)
  
$
(8,883
)
  
$
(7,297
)
                                 
Shares used in net loss per share
    
8,608,937
      
8,502,201
      
8,599,520
      
8,502,184
  
                                 
Non-GAAP net loss per share
  
$
(0.42
)
  
$
(0.40
)
  
$
(1.03
)
  
$
(0.86
)


   
Three Months Ended
    
Six Months Ended
  
   
June 30,
    
June 30,
    
June 30,
    
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
Dollars in thousands
  

$
   
% of revenue
    

$
   
% of revenue
    

$
   
% of revenue
    

$
   
% of revenue
  
                                                         
GAAP operating loss
  
$
(4,443
)
    
(66.2
)%
  
$
(5,158
)
    
(385.8
)%
  
$
(10,945
)
    
(91.3
)%
  
$
(9,533
)
    
(371.4
)%
                                                                 
Amortization of intangible assets
    
832
      
12.4
%
    
-
      
-
      
1,663
      
13.9
%
    
-
      
-
  
M&A transaction
    
-
      
-
      
894
      
66.9
%
    
(467
)
    
(3.9
)%
    
1,044
      
40.7
%
Integration/Rebranding costs
    
-
      
-
      
-
      
-
      
236
      
2.0
%
    
-
      
-
  
Remeasurement of earnout liability
    
(488
)
    
(7.3
)%
    
-
      
-
      
(492
)
    
(4.1
)%
    
-
      
-
  
Stock-based compensation expenses
    
376
      
5.6
%
    
318
      
23.8
%
    
757
      
6.3
%
    
622
      
24.2
%
                                                                 
Non-GAAP operating loss
  
$
(3,723
)
    
(55.5
)%
  
$
(3,946
)
    
(295.1
)%
  
$
(9,248
)
    
(77.1
)%
  
$
(7,867
)
    
(306.5
)%

   
Three Months Ended
    
Six Months Ended
  
   
June 30,
    
June 30,
    
June 30,
    
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
Dollars in thousands
  

$
   
% of revenue
    

$
   
% of revenue
    

$
   
% of revenue
    

$
   
% of revenue
  
                                                         
GAAP gross profit
  
$
2,757
      
41.1
%
  
$
576
      
43.1
%
  
$
4,152
      
34.6
%
  
$
1,147
      
44.7
%
Adjustments:
                                                                
Amortization of intangible assets
    
383
      
5.7
%
    
-
      
-
      
766
      
6.4
%
    
-
      
-
  
Stock-based compensation expenses
    
5
      
0.1
%
    
3
      
0.2
%
    
9
      
0.1
%
    
1
      
-
  
                                                                 
Non-GAAP gross profit
  
$
3,145
      
46.9
%
  
$
579
      
43.3
%
  
$
4,927
      
41.1
%
  
$
1,148
      
44.7
%

   
Three Months Ended
    
Six Months Ended
  
   
June 30,
    
June 30,
    
June 30,
    
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
Dollars in thousands
  

$
   
% of revenue
    

$
   
% of revenue
    

$
   
% of revenue
    

$
   
% of revenue
  
                                                         
GAAP research & development
  
$
1,205
      
18.0
%
  
$
816
      
61.0
%
  
$
2,496
      
20.8
%
  
$
1,568
      
61.1
%
Adjustments:
                                                                
Stock-based compensation expenses
    
(46
)
    
(0.7
)%
    
(34
)
    
(2.5
)%
    
(92
)
    
(0.8
)%
    
(66
)
    
(2.6
)%
                                                                 
Non-GAAP research & development
  
$
1,159
      
17.3
%
  
$
782
      
58.5
%
  
$
2,404
      
20.0
%
  
$
1,502
      
58.5
%




   
Three Months Ended
    
Six Months Ended
  
   
June 30,
    
June 30,
    
June 30,
    
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
Dollars in thousands
  
$
    
% of revenue
    
$
    
% of revenue
    
$
    
% of revenue
    
$
    
% of revenue
  
                                                         
GAAP sales & marketing
  
$
4,403
      
65.6
%
  
$
2,504
      
187.3
%
  
$
9,417
      
78.5
%
  
$
4,988
      
194.3
%
Adjustments:
                                                                
Amortization of intangible assets
    
(383
)
    
(5.7
)%
    
-
      
-
      
(765
)
    
(6.4
)%
    
-
      
-
  
Integration/Rebranding costs
    
-
      
-
      
-
      
-
      
(193
)
    
(1.6
)%
    
-
      
-
  
Stock-based compensation expenses
    
(107
)
    
(1.6
)%
    
(83
)
    
(6.2
)%
    
(218
)
    
(1.8
)%
    
(164
)
    
(6.4
)%
                                                                 
Non-GAAP sales & marketing
  
$
3,913
      
58.3
%
  
$
2,421
      
181.1
%
  
$
8,241
      
68.7
%
  
$
4,824
      
187.9
%

   
Three Months Ended
    
Six Months Ended
  
   
June 30,
    
June 30,
    
June 30,
    
June 30,
  
   
2024
    
2023
    
2024
    
2023
  
Dollars in thousands
  
$
    
% of revenue
    
$
    
% of revenue
    
$
    
% of revenue
    
$
    
% of revenue
  
                                                         
GAAP general & administrative
  
$
1,592
      
23.7
%
  
$
2,414
      
180.6
%
  
$
3,184
      
26.6
%
  
$
4,124
      
160.7
%
Adjustments:
                                                                
M&A transaction
   
-
      
-
      
(894
)
    
(66.9
)%
    
467
      
3.9
%
    
(1,044
)
    
(40.7
)%
Amortization of intangible assets
    
(66
)
    
(1.0
)%
    
-
      
-
      
(132
)
    
(1.1
)%
    
-
      
-
  
Integration/Rebranding costs
    
-
      
-
      
-
      
-
      
(43
)
    
(0.4
)%
    
-
      
-
  
Remeasurement of earnout liability
    
488
      
7.3
%
    
-
      
-
      
492
      
4.1
%
    
-
      
-
  
Stock-based compensation expenses
    
(218
)
    
(3.3
)%
    
(198
)
    
(14.8
)%
    
(438
)
    
(3.7
)%
    
(391
)
    
(15.2
)%
                                                                 
Non-GAAP general & administrative
  
$
1,796
      
26.7
%
  
$
1,322
      
98.9
%
  
$
3,530
      
29.4
%
  
$
2,689
      
104.8
%



EX-101.SCH 3 rwlk-20240815.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 rwlk-20240815_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 rwlk-20240815_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00005.jpg begin 644 image00005.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Document and Entity Information
Jun. 27, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 15, 2024
Entity File Number 001-36612
Entity Registrant Name ReWalk Robotics Ltd.
Entity Central Index Key 0001607962
Entity Incorporation, State or Country Code L3
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One 200 Donald Lynch Blvd. Marlborough, MA
Entity Address, Address Line Two Floor 6
Entity Address, City or Town Yokneam Ilit
Entity Address, Country IL
Entity Address, Postal Zip Code 01752
City Area Code 508.251.1154
Local Phone Number 4.959.0123
Title of 12(b) Security Ordinary Shares, par value NIS 0.25
Trading Symbol LFWD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://rewalk.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports rwlk-20240815.xsd rwlk-20240815_lab.xml rwlk-20240815_pre.xml zk2431866.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "zk2431866.htm": { "nsprefix": "rwlk", "nsuri": "http://rewalk.com/20240815", "dts": { "schema": { "local": [ "rwlk-20240815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "rwlk-20240815_lab.xml" ] }, "presentationLink": { "local": [ "rwlk-20240815_pre.xml" ] }, "inline": { "local": [ "zk2431866.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2023": 9 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://rewalk.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240627to20240627", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431866.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240627to20240627", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431866.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001178913-24-002647-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001178913-24-002647-xbrl.zip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end XML 18 zk2431866_htm.xml IDEA: XBRL DOCUMENT 0001607962 2024-06-27 2024-06-27 false 0001607962 00-0000000 Floor 6 Yokneam Ilit IL 4.959.0123 Ordinary Shares, par value NIS 0.25 NASDAQ 8-K 2024-08-15 ReWalk Robotics Ltd. L3 001-36612 200 Donald Lynch Blvd. Marlborough, MA 01752 508.251.1154 LFWD false false false false false